ロード中...
A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III
Conventionally, evaluation of a new drug, A, is done in three phases. Phase I is based on toxicity to determine a “maximum tolerable dose” (MTD) of A, phase II is conducted to decide whether A at the MTD is promising in terms of response probability, and if so a large randomized phase III trial is c...
保存先:
| 出版年: | Biometrics |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486466/ https://ncbi.nlm.nih.gov/pubmed/30367457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/biom.12994 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|